To examine the relationship between ocular surface disease (OSD) and topical antiglaucoma therapy.
Methods
A total of 211 eyes of 211 patients with open-angle glaucoma or ocular hypertension on topical medication were recruited over 10 months. Controls were 51 eyes of 51 healthy age- and sex-matched volunteers. In each patient, we recorded the intraocular pressure-lowering eyedrops used, the number of medications used, and daily and cumulative preservative concentrations (PC). Main outcome measures were fluorescein corneal staining score (Oxford scale), lower tear meniscus height (LTMH) (spectral-domain optical coherence tomography), noninvasive tear film breakup time (NI-TBUT) (Oculus Keratograph 5M), and OSD symptom questionnaire index (OSDI).
Results
Compared to controls, significantly higher OSDI (median [interquartile range] 10.24 [4.54-18.94] vs 2.5 [0-12.5]; p<0.001) and corneal staining (≥1: 64.93% vs 32.61%; p<0.001) scores were recorded in the medication group. The NI-TBUT and LTMH failed to vary between the groups (p>0.05). A higher daily PC was associated with a lower LTMH (R −0.142; p = 0.043). In the medication group, multivariate analysis identified correlations between benzalkonium chloride (BAK) (odds ratio [OR] 1.56) and BAK plus polyquaternium-containing drops (OR 5.09) or higher OSDI (OR 1.06) and abnormal corneal staining test results and between older age (mean ratio [MR] 1.05), longer treatment duration (MR 1.02), or corneal staining presence (MR 1.22) and a higher OSDI score.
Conclusions
Ocular surface disease was more prevalent in the medication group. The main factors impacting OSD were drops with preservatives, longer treatment duration, and older age.
QuigleyHANumber of people with glaucoma worldwide.Br J Ophthalmol. 1996;80(5):389–393.
2.
TielschJMSommerAKatzJRoyallRMQuigleyHAJavittJRacial variations in the prevalence of primary open-angle glaucoma.The Baltimore Eye Survey. JAMA. 1991;266(3):369–374.
3.
LempMBaudouinCBaumJet al.The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007).Ocul Surf. 2007;5(2):75–92.
4.
PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.Br J Ophthalmol. 2002;86(4):418–423.
5.
FurrerPMayerJMGurnyROcular tolerance of preservatives and alternatives.Eur J Pharm Biopharm. 2002;53(3):263–280.
6.
ChawlaAMcGalliardJNBatterburyMUse of eyedrops in glaucoma: how can we help to reduce non-compliance?Acta Ophthalmol Scand. 2007;85(4):464.
7.
MiljanovićBDanaRSullivanDASchaumbergDAImpact of dry eye syndrome on vision-related quality of life.Am J Ophthalmol. 2007;143(3):409–415.
8.
AritaRItohKMaedaSet al.Effects of long-term topical anti-glaucoma medications on meibomian glands.Graefes Arch Clin Exp Ophthalmol. 2012;250(8):1181–1185.
9.
AritaRItohKMaedaSet al.Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands.Cornea. 2012;31(11):1229–1234.
10.
HerrerasJMPastorJCCalongeMAsensioVMOcular surface alteration after long-term treatment with an antiglaucomatous drug.Ophthalmology. 1992;99(7):1082–1088.
11.
TeraiNMüller-HolzMSpoerlEPillunatLEShort-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects.Clin Ophthalmol. 2011;5:517–525.
12.
ServatJJBernardinoCREffects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.Drugs Aging. 2011;28(4):267–282.
13.
StewartWCStewartJANelsonLAOcular surface disease in patients with ocular hypertension and glaucoma.Curr Eye Res. 2011;36(5):391–398.
14.
ClouzeauCGodefroyDRianchoLRostèneWBaudouinCBrignole-BaudouinFHyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro.Mol Vis. 2012;18:851–863.
15.
PellinenPHuhtalaATolonenALokkilaJMäenpääJUusitaloHThe cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.Curr Eye Res. 2012;37(2):145–154.
16.
PaimelaTRyhänenTKauppinenAMarttilaLSalminenAKaarnirantaKThe preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells.Mol Vis. 2012;18:1189–1196.
17.
LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patients.J Glaucoma. 2008;17(5):350–355.
18.
SkalickySEGoldbergIMcCluskeyPOcular surface disease and quality of life in patients with glaucoma.Am J Ophthalmol. 2012;153(1):1–9e2.
19.
MathewsPMRamuluPYFriedmanDSUtineCAAkpekEKEvaluation of ocular surface disease in patients with glaucoma.Ophthalmology. 2013;120(11):2241–2248.
20.
ValenteCIesterMCorsiERolandoMSymptoms and signs of tear film dysfunction in glaucomatous patients.J Ocul Pharmacol Ther. 2011;27(3):281–285.
21.
CampAWellikSRTzuJHet al.Dry eye specific quality of life in veterans using glaucoma drops.Cont Lens Anterior Eye. 2015;38(3):220–225.
22.
SaadeCELariHBBerezinaTLFechtnerRDKhouriASTopical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.Can J Ophthalmol. 2015;50(2):132–136.
23.
Garcia-FeijooJSampaolesiJRA multicenter evaluation of ocular surface disease prevalence in patients with glaucoma.Clin Ophthalmol. 2012;6:441–446.
24.
FechtnerRDGodfreyDGBudenzDStewartJAStewartWCJasekMCPrevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.Cornea. 2010;29(6):618–621.
25.
CvenkelBŠtunfŠSrebotnik KirbišIStrojan FležarMSymptoms and signs of ocular surface disease related to topical medication in patients with glaucoma.Clin Ophthalmol. 2015;9:625–631.
26.
GhoshSOHareFLamoureuxEVajpayeeRBCrowstonJGPrevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication.Clin Exp Ophthalmol. 2012;40(7):675–681.
27.
LemijHGHoevenaarsJGvan derWindt CBaudouinCPatient satisfaction with glaucoma therapy: reality or myth?Clin Ophthalmol. 2015;9:785–793.
28.
BittonEKeechASimpsonTJonesLVariability of the analysis of the tear meniscus height by optical coherence tomography.Optom Vis Sci. 2007;84(9):903–908.
29.
ZhouSLiYLuATet al.Reproducibility of tear meniscus measurement by Fourier-domain optical coherence tomography: a pilot study.Ophthalmic Surg Lasers Imaging. 2009;40(5):442–447.
30.
TittlerEHBujakMCNguyenPet al.Between-grader repeatability of tear meniscus measurements using Fourier-domain OCT in patients with dry eye.Ophthalmic Surg Lasers Imaging. 2011;42(5):423–427.
31.
Arriola-VillalobosPFernández-VigoJIDíaz-ValleDPeraza-NievesJEFernández-PérezCBenítez-Del-CastilloJMAssessment of lower tear meniscus measurements obtained with Keratograph and agreement with Fourier-domain optical-coherence tomography.Br J Ophthalmol. 2015;99(8):1120–1125.
32.
HongJSunXWeiAet al.Assessment of tear film stability in dry eye with a newly developed keratograph.Cornea. 2013;32(5):716–721.
33.
MishimaSGassetAKlyceSDJrBaumJLDetermination of tear volume and tear flow.Invest Ophthalmol. 1966;5(3):264–276.
34.
GermanEJHurstMAWoodDReliability of drop size from multi-dose eye drop bottles: is it cause for concern?Eye(Lond). 1999;13(Pt 1):93–100.
35.
KohSIkedaCWatanabeSet al.Effect of non-invasive tear stability assessment on tear meniscus height.Acta Ophthalmol. 2015;93(2):e135–e139.
36.
SchiffmanRMChristiansonMDJacobsenGHirschJDReisBLReliability and validity of the Ocular Surface Disease Index.Arch Ophthalmol. 2000;118(5):615–621.
37.
BrewittHSistaniFDry eye disease: the scale of the problem.Surv Ophthalmol. 2001;45(Suppl 2):S199–S202.
38.
MartoneGFrezzottiPTosiGMet al.An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.Am J Ophthalmol. 2009;147(4):725–735e1.
39.
KozobolisVPDetorakisETMaskalerisGet al.Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.Am J Ophthalmol. 2005;139(4):742–743.
40.
RossiGCTinelliCPasinettiGMMilanoGBianchiPEDry eye syndrome-related quality of life in glaucoma patients.Eur J Ophthalmol. 2009;19(4):572–579.
41.
DoughertyBENicholsJJNicholsKKRasch analysis of the Ocular Surface Disease Index (OSDI).Invest Ophthalmol Vis Sci. 2011;52(12):8630–8635.
42.
BaffaLdoPRicardoJRDiasACet al.Tear film and ocular surface alterations in chronic users of antiglaucoma medications.Arq Bras Oftalmol. 2008;71(1):18–21.
43.
LeeSYWongTTChuaJBooCSohYFTongLEffect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity.Eye (Lond). 2013;27(10):1142–1150.
44.
UzunosmanogluEMocanMCKocabeyogluSKarakayaJIrkecMMeibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications.Cornea. 2016;35(8):1112–1116.
45.
TomićMKaštelanSSoldoKMSalopek-RabatićJInfluence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma.Biomed Res Int. 2013;2013:603782.
46.
LanWLinLYangXYuMAutomatic noninvasive tear breakup time (TBUT) and conventional fluorescent TBUT.Optom Vis Sci. 2014;91(12):1412–1418.
